22 results on '"Friedland D"'
Search Results
2. A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa).
3. Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
4. Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial
5. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
6. Cytotoxic chemotherapy with androgen deprivation for biochemically recurrent prostate cancer following radical prostatectomy: A retrospective review
7. Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial
8. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis
9. Phase I and pharmacokinetic (PK) study of 17-allylamino-17 demethoxygeldanamycin (17-AAG) in combination with weekly paclitaxel for advanced solid malignancies
10. Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer
11. A phase II trial of oxaliplatin and docetaxel in patients with androgen independent prostate cancer (AIPC) who have progressed to two prior regimens of chemotherapy
12. Age and body composition related-effects on the pharmacokinetic disposition of STEALTH liposomal CKD- 602 (S-CKD602) in patients with advanced solid tumors
13. Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case series
14. Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
15. A phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens
16. Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors
17. Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
18. Phase I trial of motexafin gadolinium (MGd) and docetaxel (D) chemotherapy in the treatment of advanced solid tumors
19. Phase I/II study of trimetrexate (TMTX) and capecitabine (CAP) as second and third- line therapy in patients with advanced colorectal cancer (CRC)
20. Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors
21. Phase I/II study of trimetrexate (TMTX) and capecitabine (CAP) as second and third- line therapy in patients with advanced colorectal cancer (CRC)
22. Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.